BridgeBio Inc., founded in 2015, develops biopharmaceutical therapies for genetic diseases and genetically driven cancers by translating early-stage academic research into medicines. The company operates through a hub-and-spoke model in which a central hub provides clinical, regulatory, and commercial expertise while autonomous spokes focus on specific conditions or drug candidates. This structure allows BridgeBio to pursue multiple development paths simultaneously whilst reducing the risk inherent in early-stage research.
The company has secured three FDA approvals and has more than 2,000 patients enrolled in clinical trials globally. Its pipeline includes programmes targeting limb-girdle muscular dystrophy type 2I, hereditary transthyretin-mediated amyloidosis, and achondroplasia. Research underpinning the company's work has generated more than 70 peer-reviewed publications, reflecting its grounding in academic collaboration and rigorous scientific development.
BridgeBio operates globally and brings together expertise across biopharmaceutical drug development, translational research, clinical development, regulatory affairs, and commercialization. The company's approach emphasises rapid translation of discovery into patient benefit whilst maintaining the ability to pivot development strategies as evidence accumulates.
